abil
deliv
therapeut
sitespecif
vivoremain
major
challeng
treatment
malign
inflammatori
cardiovascular
degen
diseas
need
target
agent
safe
effici
select
becom
increasingli
evid
progress
vascular
target
vascular
endothelium
central
target
intervent
given
multipl
role
physiolog
health
pathophysiolog
diseas
direct
access
circul
ligand
cancer
express
specif
molecul
surfac
vascular
endotheli
perivascular
cell
might
enabl
direct
therapeut
target
use
vivo
phage
display
significantli
contribut
identif
target
success
use
direct
vascular
target
preclin
anim
model
sever
anim
studi
perform
use
fuse
molecul
tumor
endotheliumdirect
molecul
immunomodulatori
procoagul
cytotox
molecul
addit
deliveri
therapeut
agent
vascular
target
gene
therapi
base
liganddirect
deliveri
gene
vector
tumor
endothelium
transcript
target
also
emerg
review
discuss
liganddirect
vascular
target
strategi
emphasi
recent
develop
relat
phagedisplaybas
screen
trend
cardiovasc
med
elsevi
inc
search
anticanc
therapeut
agent
target
tumor
cell
specif
select
limit
toxic
long
quest
oncolog
system
cytotox
target
cancer
cell
select
lead
advers
effect
narrow
therapeut
window
develop
target
anticanc
drug
improv
discrimin
tumor
cell
nonmalign
cell
arguabl
one
import
goal
current
anticanc
research
chemotherapeut
agent
preferenti
accumul
diseas
site
inde
dose
reach
tumor
normal
per
gram
tissu
may
littl
dose
accumul
normal
organ
bosslet
et
al
high
interstiti
pressur
irregular
tumor
vasculatur
may
account
least
part
poor
drug
uptak
tumor
cell
jain
folli
et
al
moreov
activ
multidrug
resist
mechan
may
decreas
drug
uptak
bradley
et
al
one
avenu
toward
develop
select
anticanc
drug
consist
target
deliveri
bioactiv
molecul
includ
limit
drug
cytokin
procoagul
factor
photosensit
radionuclid
etc
tumor
environ
mean
bind
molecul
specif
tumorassoci
marker
search
novel
target
cell
surfac
receptor
ligand
import
develop
strategi
convert
ligand
capabl
select
home
tumor
environ
therapeut
agent
ligandbas
tumor
target
approach
enabl
ligand
local
tumor
microenviron
tumortocontrol
organ
ratio
reach
hour
intraven
administr
buchegg
et
al
wu
et
al
adam
king
et
al
tarli
et
al
demarti
et
al
carnemolla
et
al
sever
malign
cardiovascular
inflammatori
degen
diseas
character
onset
mark
angiogenesi
folkman
cancer
long
propos
angiogenesi
contribut
tumor
progress
promot
primari
tumor
growth
metastat
dissemin
folkman
tumor
growth
requir
format
new
blood
vessel
process
neovascular
angiogenesi
appear
essenti
solid
tumor
tumor
endotheli
cell
central
neovascular
process
tumor
cell
promot
new
blood
vessel
format
releas
endotheli
cell
growth
factor
support
endotheli
cell
prolifer
migrat
surviv
solid
tumor
vasculatur
attract
target
vascular
endothelium
compos
genet
stabl
nontransform
cell
presum
less
adapt
tumor
cell
less
like
acquir
drug
resist
st
croix
et
al
kolonin
et
al
although
notion
recent
challeng
hida
klagsburn
addit
endotheli
cell
line
tumor
blood
vessel
directli
access
drug
via
system
circul
express
sever
cell
surfac
marker
absent
bare
detect
establish
quiescent
blood
vessel
liganddirect
vascular
target
accomplish
antibodi
specif
peptid
growth
factor
complex
immunomodulatori
procoagul
cytotox
molecul
thorp
burrow
brekken
thorp
thorp
et
al
thorp
target
molecul
select
upregul
angiogen
tumor
endotheli
cell
includ
av
integrin
vascular
endotheli
growth
factor
vegf
receptor
cell
adhes
molecul
vascular
cell
adhes
molecul
vcam
eselectin
molecul
associ
procoagul
chang
angiogen
endothelium
phosphatidylserin
thorp
brekken
et
al
identifi
specif
target
angiogen
tumor
endothelium
gather
inform
cellular
distribut
locat
phage
display
extens
use
zurita
et
al
final
phage
display
technolog
also
use
map
human
vascular
divers
zurita
et
al
pentz
et
al
therapeut
potenti
approach
aim
interfer
blood
suppli
easili
appreci
one
consid
estim
tumor
cell
fed
singl
endotheli
cell
folkman
thu
number
endotheli
target
cell
limit
contrast
number
tumor
cell
kill
tumor
celldirect
approach
proof
concept
mani
studi
support
hypothesi
put
forward
decad
ago
select
interf
tumor
blood
suppli
would
lead
strong
antitumor
effect
specif
vascular
target
identifi
sever
differ
effector
molecul
could
target
tumor
vasculatur
includ
radiolabel
cytotox
agent
oh
et
al
veenenda
et
al
well
antiangiogen
immunostimulatori
cytokin
halin
et
al
anoth
notabl
effector
molecul
tissu
factor
tf
initi
blood
coagul
cascad
semin
work
cell
surfac
domain
tf
target
tumor
blood
vessel
huang
et
al
truncat
extracellular
domain
tf
solubl
five
order
magnitud
less
potent
membran
form
tffactor
viia
complex
requir
neg
charg
cell
surfac
phospholipid
activ
downstream
factor
ix
x
turn
catalyz
format
thrombin
ruf
et
al
solubl
tf
target
tumor
vasculatur
initi
explos
coagul
cascad
lead
intravascular
thrombosi
tumor
infarct
ran
et
al
target
tf
tumor
vessel
accomplish
antibodi
peptid
tumor
vasculatur
marker
includ
major
histocompat
complex
class
ii
burrow
thorp
dienst
et
al
also
evalu
novel
singlechain
antibodysolubl
tf
fusion
protein
tumor
vascular
target
agent
type
transmembran
glycoprotein
gener
express
quiescent
endothelium
induc
inflamm
tumor
vasculatur
tumor
cell
gener
express
author
observ
tumor
tissu
necrosi
intratumor
vascular
fibrin
thrombosi
singl
system
administr
infus
protein
addit
longterm
treatment
produc
delay
tumor
growth
certain
condit
note
extens
analys
author
could
find
evid
treatmentrel
vascular
thrombosi
necrosi
normal
tissu
evid
system
activ
coagul
cascad
work
add
support
notion
strategi
aim
produc
vascular
occlus
tumor
tissu
effect
select
anoth
eleg
studi
hu
et
al
compar
therapeut
potenc
three
recombin
fusion
protein
consist
truncat
tf
fuse
argglyasp
rgd
tripeptidetarget
integrin
antibodi
dna
expos
degen
area
edb
domain
fibronectin
nilsson
et
al
interestingli
although
fibronectinand
avintegrintarget
tissu
factor
induc
thrombosi
smalland
mediums
blood
vessel
dnatarget
tissu
factor
larg
blood
vessel
combin
three
socal
bcoaguligandsq
effect
treatment
strategi
inhibit
tumor
outgrowth
thu
possibl
control
vascular
divers
endothelium
tumor
progress
requir
multitarget
approach
phage
display
technolog
present
rapid
mean
protein
peptid
bind
specif
predefin
molecular
target
select
isol
complex
combinatori
peptid
librari
phage
display
librari
consist
polypeptid
express
within
coat
protein
filament
bacteriophag
minor
piii
coat
protein
mani
uniqu
peptid
sequenc
display
surfac
phage
particl
zacher
et
al
scott
smith
zurita
et
al
identifi
probe
home
select
variou
vascular
bed
normal
tumor
angiogen
vasculatur
group
other
develop
vivo
phage
display
technolog
isol
peptid
bind
select
target
receptor
express
certain
blood
vessel
tissuespecif
rajott
et
al
angiogenesisrel
pasqualini
et
al
r
ap
et
al
koivunen
et
al
et
al
vascular
ligand
receptor
pair
identifi
technolog
method
phage
librari
directli
administ
mice
tail
vein
tissu
collect
examin
phage
bound
tissuespecif
endotheli
cell
marker
within
short
circul
time
min
phage
particl
unlik
abl
leav
circul
thu
perfus
phage
popul
bound
endothelium
vascular
receptor
recov
tissu
vivo
pan
advantag
isol
phagedisplay
peptid
home
select
bintactq
target
interest
moreov
ligand
peptid
may
use
function
analysi
correspond
receptor
potenti
identif
novel
drug
target
candid
isol
peptid
found
bind
endotheli
receptor
express
vasculatur
specif
tissu
although
monoclon
antibodi
demonstr
clinic
potenti
tumortarget
agent
poor
tumor
penetr
antibodi
due
size
molecul
liverbon
marrow
toxic
nonspecif
uptak
antibodi
remain
two
major
limit
antibodybas
therapi
shockley
et
al
peptid
target
agent
may
eas
problem
associ
antibodi
cancer
therapi
peptid
obtain
vivo
phage
display
technolog
exert
anticanc
effect
inhibit
angiogenesi
decreas
tumor
metastasi
activ
inhibit
enzym
import
neoplast
cell
spread
also
use
target
molecul
receptortarget
toxin
gene
therapi
imag
andor
therapeut
agent
nanomed
devic
thu
approach
provid
straightforward
way
identifi
drugaccess
tumor
cell
surfac
receptor
discov
peptid
ligand
serv
mimet
prototyp
drug
unlik
genom
proteomicbas
approach
reli
differenti
express
level
transcript
protein
product
discoveri
platform
directli
address
function
proteinprotein
interact
level
physic
bind
contrast
protein
array
system
possibl
select
bind
peptid
even
ligandreceptor
interact
mediat
conform
rather
linear
epitop
summari
liganddirect
screen
combinatori
librari
tumor
cell
surfac
may
lead
improv
select
function
relev
peptid
develop
target
bdruggableq
molecular
target
introduct
vivo
biopan
peptid
phagedisplay
librari
pasqualini
ruoslahti
sever
vascular
target
peptid
introduc
organor
tumorspecif
vascular
target
agent
addit
mani
ligandreceptor
pair
identifi
tabl
identifi
peptid
select
target
normal
organ
mice
far
prostat
kidney
skin
pancrea
retina
intestin
uteru
adren
gland
target
manner
kolonin
et
al
result
indic
vascular
endothelium
normal
organ
modifi
way
enabl
differenti
target
peptid
probe
recent
group
use
vivo
phage
display
isol
peptid
motif
ckggrakdc
home
white
fat
vasculatur
target
prohibitin
multifunct
membran
protein
tabl
ckggrakdc
sequenc
conjug
apoptosisinduc
peptid
klaklak
caus
ablat
white
fat
kolonin
et
al
also
devis
mean
identifi
peptid
home
angiogen
vasculatur
tumor
tabl
moreov
assembl
panel
peptid
motif
target
blood
vessel
tumor
xenograft
review
kolonin
et
al
motif
includ
sequenc
cdcrgdcfc
term
ngr
cprece
gsl
peptid
previous
identifi
select
bind
av
integrin
shown
home
vasculatur
tumor
xenograft
nude
mice
tumor
home
possibl
av
integrin
play
import
role
angiogenesi
integrin
absent
express
low
level
normal
endotheli
cell
induc
angiogen
vasculatur
tumor
pasqualini
et
al
brook
et
al
b
hamm
et
al
wickham
et
al
sipkin
et
al
hood
et
al
dickerson
et
al
phage
display
doubl
cyclic
peptid
exhibit
time
higher
tumorhom
abil
neg
control
phage
pasqualini
et
al
date
integrin
vegf
receptor
edb
domain
fibronectin
extens
studi
target
deliveri
toxic
drug
tumor
endotheli
cell
report
cyclic
cngrc
conjug
chemotherapeut
drug
doxorubicin
proapoptot
peptid
klaklak
increas
therapeut
index
reduc
toxic
vivo
ellerbi
et
al
moreov
ngr
peptid
shown
improv
antitumor
effect
tumor
necrosi
factor
interferonc
fuse
cytokin
curni
et
al
curni
et
al
recent
identifi
aminopeptidas
angiogen
receptor
ngr
motif
pasqualini
et
al
aminopeptidas
apa
angiogen
receptor
cpreces
motif
et
al
group
show
apa
strongli
upregul
angiogen
tumor
blood
vessel
bare
detect
normal
blood
vessel
enzymat
activ
apa
coloc
express
pattern
human
tumor
show
cpreces
motif
inhibit
enzymat
activ
home
tumor
vasculatur
vivo
inhibit
tumor
growth
et
al
target
tumor
blood
vessel
turn
matrix
metalloproteinas
koivunen
et
al
et
al
similarli
select
peptid
inhibitor
gelatinas
local
murin
tumor
prevent
tumor
growth
upon
intraven
inject
koivunen
et
al
studi
clearli
show
av
integrin
aminopeptidas
n
aminopeptidas
specif
express
angiogen
endotheli
cell
pericyt
human
murin
tissu
origin
marker
angiogen
neovasculatur
either
express
low
level
nonprolifer
endotheli
cell
interestingli
mani
tumor
vascular
marker
proteas
somewhat
intuit
given
malign
tumor
invas
marker
also
serv
viral
receptor
av
integrin
receptor
adenovirus
wickham
et
al
receptor
coronavirus
yeager
et
al
recent
shown
receptor
echovirus
pulli
et
al
tempt
specul
bacteriophag
ie
prokaryot
virus
may
use
cellular
receptor
eukaryot
virus
fact
structur
phage
capsid
protein
provid
good
evid
bacteriophag
share
ancestri
anim
virus
hendrix
evolutionari
biolog
footnot
find
suggest
receptor
isol
vivo
phage
display
cell
intern
capabl
key
featur
one
wish
use
peptid
motif
therapi
carrier
target
select
cell
subpopul
protein
serv
vascular
target
burg
et
al
isol
peptid
bind
vitro
proteoglycan
select
express
angiogen
vasculatur
demonstr
home
peptid
mous
tumor
avoid
challeng
speci
specif
start
program
cancer
patient
use
vivo
phage
display
approach
human
group
report
first
vivo
screen
peptid
librari
patient
led
identif
pentz
et
al
mimic
motif
interleukin
prostat
biopsi
also
demonstr
phage
mimic
display
cyclic
peptid
cgrraggsc
bound
specif
correspond
receptor
potenti
target
intervent
human
prostat
cancer
zurita
et
al
cancer
express
tumor
antigen
immun
respons
antigen
explor
identifi
marker
diseas
aggress
target
therapi
report
methodolog
select
peptid
motif
recogn
tumorassoci
antibodi
phagedisplaybas
approach
term
fingerprint
enabl
isol
mimic
peptid
antigen
elicit
humor
respons
mintz
et
al
method
antibodi
fingerprint
combinatori
screen
phage
display
random
peptid
librari
select
vitro
pool
immobil
patientderiv
immunoglobulin
thu
fingerprint
circul
repertoir
antibodi
patient
prostat
cancer
identifi
glucoseregul
relev
molecular
target
express
metastat
tumor
mintz
et
al
synthet
chimer
peptid
compos
bind
motif
fuse
proapoptot
peptid
suppress
tumor
growth
mice
arap
et
al
also
fingerprint
pool
antibodi
purifi
patient
ovariancancerderiv
ascit
vidal
et
al
identifi
peptid
motif
mimick
heatshock
protein
kda
report
implic
cancer
kamal
et
al
found
wide
express
ovarian
cancer
humor
respons
tumorassoci
stagespecif
data
obtain
variou
peptid
phage
display
screen
support
potenti
target
ligand
drug
develop
clinic
applic
final
group
develop
novel
technolog
term
biopan
rapid
analysi
select
interact
ligand
enabl
fast
select
peptid
bind
cell
surfac
receptor
giordano
et
al
biopan
rapid
analysi
select
interact
ligand
base
differenti
centrifug
cell
incub
phage
aqueou
upper
phase
centrifug
nonmisc
organ
lower
phase
separ
specif
phagecel
complex
unbound
phage
method
sever
advantag
convent
method
reli
wash
step
limit
dilut
faster
sensit
specif
directli
applic
cell
like
preserv
nativ
conform
protein
potenti
isol
ligandreceptor
pair
cell
deriv
clinic
sampl
autom
highthroughput
screen
two
exampl
vast
potenti
system
offer
proof
principl
construct
ligandreceptor
map
vegfreceptor
famili
base
peptid
new
motif
target
vegf
valid
giordano
et
al
atherosclerosi
regard
dynam
progress
diseas
aris
combin
endotheli
dysfunct
inflamm
condit
lead
caus
death
develop
countri
develop
target
imag
agent
time
identif
unstabl
atherosclerot
lesion
unmet
need
ruptur
plaqu
often
result
myocardi
infarct
stroke
fuster
sever
target
nuclear
imag
agent
develop
report
highrisk
featur
atherosclerot
lesion
mari
strauss
molecular
chang
endotheli
surfac
consid
import
contributor
initi
progress
thrombot
complic
atherosclerosi
ross
fuster
howev
profil
endotheli
surfac
protein
display
atherogenesi
still
poorli
character
although
adhes
cellsurfac
glycoprotein
selectin
dong
et
al
cybulski
gimbron
appear
play
role
atherogenesi
systemat
explor
affect
endotheli
surfac
hamper
technic
limit
liu
et
al
use
vivo
phage
display
technolog
identif
peptid
probe
select
bind
atherosclerot
lesion
induc
apo
knockout
mice
cellular
event
model
thought
mimic
least
part
molecular
chang
occur
hypercholesterolem
anim
model
perhap
human
diseas
boisvert
et
al
curtiss
boisvert
strikingli
identifi
endotheli
surfac
target
one
select
peptid
peptid
preferenti
bound
ex
vivo
resect
human
arteri
atherosclerot
lesion
three
select
peptid
homolog
recapitul
bind
lesion
turn
inhibit
protein
peptid
use
target
patholog
featur
sometim
associ
angiogenesi
exampl
tepe
et
al
describ
radiolabel
endothelin
deriv
preferenti
accumul
atherosclerot
plaqu
intraven
administr
mmp
also
broadli
implic
sever
cardiovascular
diseas
includ
atherosclerosi
libbi
gali
khatri
aortic
aneurysm
pyo
et
al
heart
failur
lee
libbi
therefor
may
repres
relev
target
cardiovascular
molecular
imag
atherosclerosi
mmp
express
macrophag
vascular
cell
involv
atherosclerot
plaqu
disrupt
via
enzymat
degrad
fibrou
cap
endotheli
basement
membran
libbi
gali
khatri
among
mmp
gelatinas
b
appear
particip
sever
stage
atherosclerosi
candid
target
vivo
molecular
imag
atherosclerosi
progress
gene
therapi
depend
develop
liganddirect
vector
enabl
system
target
deliveri
gene
ration
design
construct
test
vasculartarget
gene
deliveri
vector
promis
rout
improv
safeti
efficaci
gene
therapi
would
highli
advantag
gene
deliveri
vascular
cell
could
improv
effici
thu
enabl
reduc
dose
use
potenti
reduc
immunogen
improv
select
thu
reduc
potenti
deleteri
sideeffect
transgen
express
nontarget
site
vector
target
strategi
advanc
substanti
recent
past
enabl
construct
vector
home
defin
site
vivo
system
applic
adenoviru
ad
adenoassoci
viru
aav
commonli
use
cardiovascular
gene
therapi
commonli
use
ad
vector
gene
therapi
base
serotyp
cardiovascular
diseas
adenovirus
transduc
endothelium
smooth
muscl
cell
within
blood
vessel
wall
albeit
upon
administr
high
titer
lemarchand
et
al
french
et
al
hinder
preclin
progress
ad
serotyp
vector
clinic
trial
ischemia
grine
et
al
hedman
et
al
would
therefor
benefit
cardiovascular
gene
therapi
develop
adenovirus
favor
profil
achiev
sever
way
includ
use
antibodi
retarget
viru
altern
receptor
angiotensinconvert
enzym
eselectin
harari
et
al
reynold
et
al
target
peptid
insert
hi
loop
fiber
structur
modul
receptor
bind
nicklin
et
al
molecular
adaptor
trepel
et
al
trepel
et
al
pseudotyp
involv
exchang
ad
fiber
fiber
altern
serotyp
possess
favor
cell
bind
profil
chillon
et
al
havenga
et
al
strategi
provid
proof
concept
improv
transduct
vascular
cell
nicklin
baker
recombin
aav
serotyp
yet
anoth
promis
vector
gene
therapi
achiev
longterm
stabl
transgen
express
anim
human
subject
direct
administr
vector
variou
target
tissu
kay
et
al
unfortun
endotheli
cell
appar
poorli
transduc
richter
et
al
nicklin
et
al
inde
defici
endotheli
transduct
recogn
richter
et
al
show
local
deliveri
blood
vessel
led
transduct
underli
vascular
smooth
muscl
cell
even
presenc
intact
endothelium
subsequ
studi
report
sequestr
within
extracellular
matrix
around
endotheli
cell
thu
prevent
cell
bind
entri
degrad
intern
particl
proteasom
two
factor
respons
ineffici
transduct
endotheli
cell
nicklin
et
al
pajusola
et
al
ad
strategi
includ
nongenet
modif
genet
insert
target
peptid
pseudotyp
altern
serotyp
capsid
nicklin
baker
case
target
peptid
two
main
method
assess
thu
far
vascular
cell
first
phagedisplayderiv
peptid
incorpor
capsid
posit
optim
peptid
insert
within
capsid
display
insert
peptid
surfac
virion
girod
et
al
subsequ
studi
show
increas
effici
select
endotheli
cell
transduct
vitro
vivo
intraven
administr
use
either
target
peptid
seven
residu
nicklin
et
al
eleg
altern
muller
et
al
introduc
random
peptid
librari
display
capsid
screen
aav
librari
human
primari
coronari
arteri
endotheli
cell
yield
motif
enhanc
infect
endotheli
cell
compar
nonendotheli
cell
remain
determin
whether
approach
success
vivo
muller
et
al
lieber
retrovirus
also
engin
coat
antibodi
eg
antivegf
receptor
select
gene
deliveri
tumor
endothelium
masood
et
al
combin
use
regulatori
element
control
two
independ
marker
tumor
endothelium
endoglin
gave
synergist
effect
target
specif
vitro
savontau
et
al
recent
strategi
attain
specif
effect
tumor
blood
vessel
use
tumor
cellspecif
cytotox
lymphocyt
deliv
retroviru
contain
gene
encod
vegf
toxin
fusion
protein
tumor
cell
vegf
toxin
synthes
tumor
cell
expect
destroy
adjac
tumor
endothelium
angiogen
blood
vessel
normal
tissu
distant
tumor
addit
virus
liposom
conjug
cyclic
use
deliveri
devic
select
endotheli
cell
melanoma
cell
express
integrin
fahr
et
al
peptid
contain
rgd
short
polylysin
segment
electrostat
bind
dna
effici
enhanc
transfer
dna
differ
cell
type
suh
et
al
kunath
et
al
similar
vascular
target
strategi
employ
select
deliv
gene
tumor
blood
vessel
hood
et
al
describ
use
cation
nanoparticl
complex
integrinligand
select
deliv
mutant
raf
protein
inhibit
endotheli
cell
surviv
signal
block
angiogenesi
respons
differ
growth
factor
system
administr
nanoparticl
tumorbear
mice
result
apoptosi
tumor
endothelium
lead
tumor
cell
apoptosi
even
regress
primari
metastat
tumor
similar
strategi
use
small
interf
rna
specif
knock
vegf
receptor
express
led
inhibit
tumor
outgrowth
schiffel
et
al
prokaryot
viral
vector
also
develop
deliveri
gene
eukaryot
cell
larocca
et
al
monaci
et
al
prokaryot
virus
bacteriophag
phage
might
offer
attract
altern
viral
nonvir
vector
theori
overcom
drawback
anim
vector
exampl
major
advantag
phage
eukaryot
viral
vector
lack
tropism
mammalian
cell
barrow
soothil
barba
et
al
phage
also
safe
administ
patient
evidenc
fact
human
receiv
bacteriophag
preantibiot
era
without
advers
effect
barrow
soothil
therefor
engin
deliv
gene
cell
without
need
elimin
nativ
tropism
concern
current
anim
viralvector
target
ivanenkov
et
al
poul
mark
larocca
et
al
deliveri
report
gene
achiev
genet
modifi
phage
particl
display
peptid
surfac
receptor
transferrin
epiderm
growth
factor
larocca
et
al
monaci
et
al
howev
current
phagebas
vector
otherwis
gener
consid
poor
gene
therapi
vector
recent
piersanti
et
al
report
construct
lambdaphagebas
vector
display
fulllength
penton
base
adenoviru
penton
base
mediat
attach
entri
endosom
escap
proteasom
resist
adenoviru
mammalian
cell
abl
confer
characterist
phage
particl
final
phage
particl
select
vivo
phage
display
abil
home
cell
surfac
receptor
blood
vessel
could
provid
target
system
gene
deliveri
vascular
endothelium
moreov
advantag
exist
gene
deliveri
vector
vascular
target
gene
therapi
phage
identifi
home
vascular
receptor
vivo
screen
requir
target
modif
success
combin
treatment
modal
includ
target
antivascular
agent
convent
tumor
therapi
radiochemotherapi
may
complex
dose
time
depend
depend
dose
schedul
mode
action
antiangiogenesi
antivascular
therapi
may
reduc
tumor
blood
flow
thu
decreas
tumor
dose
concurr
administ
chemotherapeut
drug
furthermor
inhibit
blood
suppli
lead
overexpress
hypoxiainduc
factor
correl
increas
tumor
invas
resist
chemotherapi
blagosklonni
semenza
tran
et
al
address
challeng
sengupta
et
al
recent
report
design
deliveri
system
term
nanocel
compris
nuclear
nanoparticl
within
extranuclear
pegyl
lipid
envelop
nanocel
enabl
first
tempor
releas
vascular
target
agent
trap
within
lipid
envelop
caus
vascular
bshutdownq
inner
nanoparticl
releas
chemotherapeut
drug
doxorubicin
kill
tumor
cell
tumorbear
mice
nanocel
treatment
show
superior
antitumor
efficaci
compar
directli
equival
dose
control
moreov
signific
increas
achiev
lifespan
tumorbear
anim
treat
nanocel
identif
vascular
marker
open
way
diagnost
therapeut
strategi
base
target
deliveri
imag
therapeut
agent
vasculatur
liganddirect
vascular
target
agent
proven
mode
action
antitumor
efficaci
sever
preclin
anim
model
current
dozen
vascular
target
agent
preclin
clinic
investig
test
system
treatment
dissemin
tumor
diseas
endotheli
cell
surfac
receptor
neovasculatur
candid
therapeut
target
cancer
last
decad
phage
display
librari
techniqu
success
use
discov
cell
surfac
bind
peptid
peptid
excel
altern
target
agent
human
cancer
may
allevi
problem
associ
antibodi
target
central
role
pathogenesi
cardiovascular
diseas
vascular
endothelium
also
quit
attract
therapeut
target
cardiovascular
diseas
genet
modul
endotheli
function
may
offer
new
opportun
modifi
cours
cardiovascular
diseas
hypertens
atherosclerosi
thrombosi
ischem
arteri
diseas
gene
therapi
promis
approach
treatment
endotheli
dysfunct
howev
success
therapi
requir
develop
vector
deliveri
tool
improv
specif
safeti
effici
gene
transfer
liganddirect
gene
deliveri
endothelium
cardiovascular
diseas
offer
uniqu
opportun
treat
cardiovascular
patholog
